- Home
- LONA vs NRXP Comparison
LONA vs NRXP Comparison
Compare LONA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LONA | NRXP |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | 26 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 62.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LONA | NRXP |
|---|---|---|
| Price | $5.67 | $1.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.00 | ★ $31.50 |
| AVG Volume (30 Days) | 47.5K | ★ 522.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $1.58 |
| 52 Week High | $6.61 | $3.84 |
Technical Indicators
Market Signals| Indicator | LONA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 41.70 |
| Support Level | $4.34 | $1.65 |
| Resistance Level | $6.13 | $2.79 |
| Average True Range (ATR) | 0.46 | 0.11 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 72.58 | 32.76 |
Price Performance
Historical ComparisonAbout LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.